OMEICOS Therapeutics raises €6.2M Series A round
15 April 2015· Berlin, Germany· health, biotech, materials, b2b, deep_hardware
The company intends to use the funds to advance its lead candidate OMT-28 for the treatment of atrial fibrillation through pre-clinical development
Investors
LeadVesalius Biocapital II
Also participating
SMS groupKfW GroupVC Fonds Technologie BerlinHigh-Tech Gründerfonds II
About OMEICOS Therapeutics
Stage
Series C
Headquarters
Berlin, Germany
Founded
2013
Team Size
6–20
Sectors
healthbiotechmaterialsb2bdeep_hardware